Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 408

1.

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.

Lancet. 1995 Dec 16;346(8990):1593-6.

PMID:
7500751
2.

Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.

Lancet. 1997 Jan 11;349(9045):83-8.

PMID:
8996419
3.
4.
5.

Estrogen and progestin components of oral contraceptives: relationship to vascular disease.

Carr BR, Ory H.

Contraception. 1997 May;55(5):267-72. Review.

PMID:
9220222
6.

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial.

Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE.

Blood. 2004 Feb 1;103(3):927-33. Epub 2003 Oct 9.

7.

Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.

Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE.

Blood Coagul Fibrinolysis. 2002 Jul;13(5):373-81.

PMID:
12138364
8.
9.

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.

Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G.

Lancet. 1999 Dec 11;354(9195):2036-40.

PMID:
10636369
10.

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.

Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC.

Br J Haematol. 1997 Apr;97(1):233-8.

PMID:
9136971
11.

Effect of oral contraceptive progestins on serum copper concentration.

Berg G, Kohlmeier L, Brenner H.

Eur J Clin Nutr. 1998 Oct;52(10):711-5.

PMID:
9805216
12.

Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?

Schambeck CM, Schwender S, Haubitz I, Geisen UE, Grossmann RE, Keller F.

Thromb Haemost. 1997 Dec;78(6):1480-3.

PMID:
9423798
14.

Third-generation oral contraceptives: how risky?

Weiss N.

Lancet. 1995 Dec 16;346(8990):1570.

PMID:
7500743
15.

Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.

Godsland IF, Crook D, Devenport M, Wynn V.

Contraception. 1995 Sep;52(3):143-9.

PMID:
7587185
16.

Factor V Leiden: should we screen oral contraceptive users and pregnant women?

Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR.

BMJ. 1996 Nov 2;313(7065):1127-30. Review.

17.
18.

Smoking and use of oral contraceptives: impact on thrombotic diseases.

Lidegaard O.

Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S357-63.

PMID:
10368521
19.
Items per page

Supplemental Content

Write to the Help Desk